Posted inBiotechnology
Posted inBiotechnology
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted…












